George Pyrgos, MD
Pulmonary Disease · Baltimore, MDNPI 1255480059
Payments from drug & device makers
What this record shows
This record is dominated by education: $27 of the $27 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, CSL Behring. That places this record below the midpoint for pulmonary disease clinicians in MD, where the typical reported total is $830.
Across 1 payment — averaging $27.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$27
Across 7 payments — averaging $9311.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$49K
- Sanofi US Services Inc.$9K
- AstraZeneca$8K
What the payments were for
- Education$27100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 1 | $27 |
How this compares
$27 in reported general payments places this provider in the 10th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 267 | $328,974 |
| Dupixent SyringeDupilumab | 32 | $142,545 |
| Dupixent PenDupilumab | 19 | $90,724 |
| XolairOmalizumab | 22 | $88,359 |
| Breo ElliptaFluticasone/Vilanterol | 113 | $70,347 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $60,040 |
| Spiriva RespimatTiotropium Bromide | 41 | $39,335 |
| Pirfenidone | 17 | $35,378 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $23,774 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $21,677 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $18,294 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 29 | $17,164 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $15,018 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $10,992 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $10,458 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Baltimore
- Alan SchwartzBaltimore$1.3M
- Hitesh BatraBaltimore$611K
- Lonny YarmusBaltimore$582K
- Robert WiseBaltimore$389K
- Ko Pen WangBaltimore$280K
- Hans LeeBaltimore$277K
- Angela ArgentoBaltimore$269K
- Michael DrummondBaltimore$263K
- Jason AkulianBaltimore$231K
- Kathryn RobinettBaltimore$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.